The financial data provided to the CODM is as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | US: | | | | | | | | | | SUBLOCADE* | | $ | 252 | | | $ | 203 | | | $ | 707 | | | $ | 561 | | | Sublingual & other | | 53 | | 51 | | 160 | | 157 | OPVEE1 | | — | | 8 | | — | | 8 | PERSERIS2 | | 2 | | 6 | | 12 | | 19 | | Total U.S. | | 307 | | 267 | | 880 | | 745 | | Rest of World | | 48 | | 47 | | 136 | | 137 | | Net revenue | | 356 | | | 314 | | | 1,016 | | | 881 | | | Cost of sales | | 51 | | | 83 | | | 140 | | | 179 | | | Gross profit | | 305 | | | 230 | | | 875 | | | 702 | | | | | | | | | | | | Operating expenses: | | | | | | | | | | Selling, general and administrative | | 119 | | | 154 | | | 364 | | | 445 | | | Research and development | | 5 | | | 33 | | | 33 | | | 76 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total operating expenses | | 125 | | | 187 | | | 398 | | | 521 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Interest (income) | | (4) | | | (6) | | | (9) | | | (16) | | | Interest expense | | 2 | | | 12 | | | 10 | | | 39 | | Loss on debt extinguishment | | — | | | — | | | 18 | | | — | | | Income before income taxes | | 182 | | | 37 | | | 457 | | | 158 | | | | | | | | | | | | Income tax expense (benefit) | | 45 | | | (5) | | | 109 | | | 50 | | | | | | | | | | | | Net income | | $ | 137 | | | $ | 42 | | | $ | 348 | | | $ | 108 | | | | | | | | | | | | *Total SUBLOCADE net revenue | | $ | 267 | | | $ | 219 | | | $ | 753 | | | $ | 604 | | | | | | | | | | | | Depreciation and amortization | | $ | 1 | | | $ | 2 | | | $ | 5 | | | $ | 8 | | | Stock-based compensation expense | | $ | 8 | | | $ | 6 | | | $ | 28 | | | $ | 21 | |
1Discontinued sales and marketing support for OPVEE® during Q3 2025. 2Marketing and promotional activities for PERSERIS were discontinued in 2024.
|